Display options
Share it on

Lipids Health Dis. 2004 Oct 04;3:21. doi: 10.1186/1476-511X-3-21.

Apolipoprotein M.

Lipids in health and disease

Guanghua Luo, Xiaoying Zhang, Peter Nilsson-Ehle, Ning Xu

Affiliations

  1. Department of Clinical Chemistry, Institute of Laboratory Medicine, University Hospital of Lund, S-221 85 Lund, Sweden. [email protected]

PMID: 15461812 PMCID: PMC523857 DOI: 10.1186/1476-511X-3-21

Abstract

Apolipoprotein M (apoM) is a 26-kDa protein that is mainly associated with high-density lipoprotein (HDL) in human plasma, with a small proportion present in triglyceride-rich lipoproteins (TGRLP) and low-density lipoproteins (LDL). Human apoM gene is located in p21.31 on chromosome 6 (chromosome 17, in mouse). Human apoM cDNA (734 base pairs) encodes 188-amino acid residue-long protein. It belongs to lipocalin protein superfamily. Human tissue expression array study indicates that apoM is only expressed in liver and in kidney and small amounts are found in fetal liver and kidney. In situ apoM mRNA hybridization demonstrates that apoM is exclusively expressed in the hepatocytes and in the tubule epithelial cells in kidney. Expression of apoM could be regulated by platelet activating factor (PAF), transforming growth factors (TGF), insulin-like growth factor (IGF) and leptin in vivo and/or in vitro. It has been demonstrated that apoM expression is dramatically decreased in apoA-I deficient mouse. Hepatocyte nuclear factor-1alpha (HNF-1alpha) is an activator of apoM gene promoter. Deficiency of HNF-1alpha mouse shows lack of apoM expression. Mutations in HNF-1alpha (MODY3) have reduced serum apoM levels. Expression of apoM is significantly decreased in leptin deficient (ob/ob) mouse or leptin receptor deficient (db/db) mouse. ApoM concentration in plasma is positively correlated to leptin level in obese subjects. These may suggest that apoM is related to the initiation and progression of MODY3 and/or obesity.

References

  1. J Biol Chem. 1999 Oct 29;274(44):31286-90 - PubMed
  2. J Intern Med. 1991 Feb;229(2):201-3 - PubMed
  3. Ann N Y Acad Sci. 2000;924:81-90 - PubMed
  4. Front Biosci. 2001 Mar 1;6:D456-504 - PubMed
  5. FEBS Lett. 2001 Jun 15;499(1-2):127-32 - PubMed
  6. Biochem Soc Symp. 2001;(67):101-9 - PubMed
  7. Scand J Clin Lab Invest. 2001 Jul;61(4):301-6 - PubMed
  8. J Biol Chem. 2001 Oct 19;276(42):38680-4 - PubMed
  9. J Biol Chem. 2001 Dec 28;276(52):49066-76 - PubMed
  10. Biochem Biophys Res Commun. 2002 Apr 12;292(4):944-50 - PubMed
  11. J Biol Chem. 2002 Oct 18;277(42):39515-24 - PubMed
  12. J Neurosci Res. 2002 Nov 1;70(3):361-6 - PubMed
  13. J Nutr Health Aging. 2002;6(6):377-82 - PubMed
  14. Acta Histochem. 2003;105(1):67-72 - PubMed
  15. Diabetes. 2003 Dec;52(12):2989-95 - PubMed
  16. Trends Cardiovasc Med. 1998 Aug;8(6):250-5 - PubMed
  17. Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R135-41 - PubMed
  18. Acta Histochem. 2004;106(2):123-8 - PubMed
  19. Neurosci Lett. 2004 Jun 10;363(2):139-43 - PubMed
  20. J Lipid Res. 2004 Jul;45(7):1272-8 - PubMed
  21. Scand J Clin Lab Invest. 2004;64(3):217-22 - PubMed
  22. Biochim Biophys Acta. 2004 Jul 5;1683(1-3):33-7 - PubMed
  23. Kidney Int. 1996 Aug;50(2):538-42 - PubMed
  24. J Biol Chem. 1997 Oct 10;272(41):25576-82 - PubMed
  25. Metabolism. 1994 Jan;43(1):90-7 - PubMed
  26. Kidney Int. 1997 Dec;52(6):1651-5 - PubMed
  27. Kidney Int. 1999 Oct;56(4):1534-43 - PubMed
  28. J Nutr Biochem. 2004 Oct;15(10):579-82 - PubMed
  29. Biochem Biophys Res Commun. 2004 Sep 3;321(4):916-21 - PubMed
  30. Nephrol Dial Transplant. 2000 Jul;15(7):940-2 - PubMed

Publication Types